Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system

Chronic myelogenous leukemia (CML) is a clonal stem cell disease caused by the BCR-ABL oncoprotein and is characterized, in its early phase, by excessive accumulation of mature myeloid cells, which eventually leads to acute leukemia. The genetic events involved in CML's progression to acute leukemia remain largely unknown. Recent studies have detected the presence of the NUP98HOXA9 fusion oncogene in acute leukemia derived from CIVIL patients, which suggests that these 2 oncoproteins may interact and influence CIVIL disease progression. Using in vitro purging of BCRABL-transduced mouse bone marrow cells, we can now report that recipients of bone marrow cells engineered to coexpress BCR-ABL with NUP98-HOXA9 develop acute leukemia within 7 to 10 days after transplantation. However, no disease is detected for more than 2 months in mice receiving bone marrow cells expressing either BCR-ABL or NUP98-HOXA9. We also provide evidence of high levels of HOXA9 expressed in leukemic blasts from acute-phase CIVIL patients and that it interacts significantly on a genetic level with BCR-ABL in our in vivo CIVIL model. Together, these studies support a causative, as opposed to a consequential, role for NUP98-HOXA9(and possibly HOXA9) in CIVIL disease progression. (Blood. 2002;100:4177-4184).